PhRMA taps BMS’s Dolan as trade group chairman

The Pharmaceutical Research and Manufacturers of America (PhRMA) has elected Peter Dolan, Bristol-Myers Squibb CEO, as chairman of the group. He replaces Bill Weldon, CEO of Johnson & Johnson, and will serve a one-year term. Others elected at the PhRMA annual meeting in Washington, DC, were Dolan’s successor, chairman-elect Kevin Sharer, who is the CEO of Amgen, and board treasurer Karen Katen, who is Pfizer’s vice chairman. Dolan set priorities such as improving patient access to medicines—as PhRMA did with its Partnership for Prescription Assistance—and developing formal pandemic response planning for rapid delivery of medicines and other support. The three board members will “focus on consistent, long-term solutions to today’s healthcare challenges that will deliver the maximum benefit to patients,” Dolan said in a statement.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.